ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 41 for:    Recruiting, Not yet recruiting, Available Studies | "Unrelated Donors"

Umbilical Cord Blood Transplantation From Unrelated Donors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03016806
Recruitment Status : Recruiting
First Posted : January 11, 2017
Last Update Posted : February 20, 2018
Sponsor:
Information provided by (Responsible Party):
Jane Liesveld, University of Rochester

Brief Summary:
This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

Condition or disease Intervention/treatment Phase
Acute Leukemia Immune Deficiency Disorder Congenital Hematological Disorder Metabolism Disorder Aplastic Anemia Myelodysplastic Syndromes Chronic Leukemia Lymphoma Multiple Myeloma Solid Tumor Radiation: Total Body Irradiation 1200 cGy Radiation: Total Body Irradiation 200 cGy Drug: Cyclophosphamide Drug: Mesna Procedure: Cord Blood Infusion Drug: Busulfan Drug: Fludarabine Drug: Melphalan Phase 1

Detailed Description:
This study is a single-center treatment protocol with four possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution. Enrolled patients will receive chemotherapy +/-total body radiation as a pre-transplant conditioning regimen. Patients will then receive cord blood stem cells followed by GvHD prophylaxis that will include Tacrolimus and Mycophenolate Mofetil, or Cyclosporin A and Methylprednisolone. Multiple data points will be collected prior to, during, and following transplantation to ensure safety of the process and to evaluate the stated objectives.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Umbilical Cord Blood Transplantation From Unrelated Donors
Study Start Date : June 2015
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2026


Arm Intervention/treatment
Full Intensity, TBI-based Conditioning
Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
Radiation: Total Body Irradiation 1200 cGy
Total Body Irradiation 1200 cGy in 8 fractions
Other Name: TBI 1200 cGy

Drug: Cyclophosphamide
50 mg/kg or 60 mg/kg
Other Name: Cy

Drug: Mesna
50 mg/kg or 60 mg/kg plus 10% loading dose
Other Name: Pre-Mesna

Procedure: Cord Blood Infusion
Intravenous infusion of cord blood stem cells

Full Intensity, Chemo-based Conditioning
Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
Drug: Cyclophosphamide
50 mg/kg or 60 mg/kg
Other Name: Cy

Drug: Mesna
50 mg/kg or 60 mg/kg plus 10% loading dose
Other Name: Pre-Mesna

Procedure: Cord Blood Infusion
Intravenous infusion of cord blood stem cells

Drug: Busulfan
0.8 mg/kg x 16 doses
Other Name: Bu

Reduced Intensity Chemotherapy
Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
Procedure: Cord Blood Infusion
Intravenous infusion of cord blood stem cells

Drug: Fludarabine
30 mg/m2/day x 5 or 40 mg/m2/day x 5
Other Name: Flu

Drug: Melphalan
140 mg/m2
Other Name: Mel

Non-Myeloablative Conditioning
Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
Radiation: Total Body Irradiation 200 cGy
Total Body Irradiation 200 cGy in one fraction
Other Name: TBI 200 cGy

Drug: Cyclophosphamide
50 mg/kg or 60 mg/kg
Other Name: Cy

Drug: Mesna
50 mg/kg or 60 mg/kg plus 10% loading dose
Other Name: Pre-Mesna

Drug: Fludarabine
30 mg/m2/day x 5 or 40 mg/m2/day x 5
Other Name: Flu




Primary Outcome Measures :
  1. Engraftment of ANC and Platelets [ Time Frame: 42 days following the infusion of stem cells for ANC [If engraftment of ANC does not occur within 42 days, a subsequent transplant will be performed if a donor is available.] ]
    The date of engraftment of ANC is the first of 3 consecutive days of ANC of 500 or higher based on daily CBC and Differential Counts. The date of engraftment of platelets is the first of three consecutive days of platelet counts of 20,000 or higher in the absence of platelet transfusions for a t least 7 days prior.


Secondary Outcome Measures :
  1. Rate of non-engraftment and of secondary graft failure [ Time Frame: At 30 days, 100 days, 6 months and yearly from the date of transplant until the date of documented graft failure or the subject's death up to 120 months. ]
    The percentage of patients who fail to initially engraft ANC will be tabulated as well as the percentage of patients who have primary engraftment of ANC but whose graft fails as evidenced by pancytopenia, failure of bone marrow function and loss of donor chimerism following initial engraftment of ANC.

  2. Incidence of acute graft-versus-host disease [ Time Frame: At 30 days and 100 days after transplant from the date of transplant until the date of documented acute GvHD. ]
    Routine physical exams, liver function tests, and clinical history of diarrhea and upper GI symptoms will be used to assess the presence of, the maximum severity of and the date of onset of Acute GvHD based on the criteria published by Przepioka et al., Bone Marrow Transplant 1995; 15(6):825-8 as used by the Center for International Blood & Marrow Transplant Research. The percentage of patients developing symptoms of acute graft-versus-host disease will be tabulated.

  3. Incidence of chronic graft-versus-host disease [ Time Frame: At 100 days, 6 months and yearly after transplant from the date of transplant until the date of documented graft failure or the subject's death up to 120 months. ]
    Assess the presence of and the maximum severity of and the date of onset of chronic GvHD based on Sullivan KM, Blood 1981;57-267 as used by the Cneter for International Blood & Marrow Transplant Research.

  4. Disease-free survival [ Time Frame: At 30 days, 100 days, 6 months and yearly after transplant from the date of transplant until the date of documented graft failure or the subject's death up to 120 months. ]
    Document and update the length of time a subject survives without recurrence of the disease for which they were transplanted at 30 days, 100 days, 6 months and yearly following the infusion of cord blood stem cells for as long as the subjects survive and remain disease-free.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Months to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited to:
  • Congenital and Other Non-malignant Disorders:
  • Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)
  • Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)
  • Metabolic disorders (e.g. Hurler's Syndrome)
  • Severe aplastic anemia
  • High-Risk Leukemia:
  • Acute Myelogenous Leukemia
  • Refractory to standard induction therapy (more than 1 cycle required to achieve remission)

    • Recurrent (in CR ≥ 2)
    • Treatment-related AML or MDS
    • Evolved from myelodysplastic syndrome
    • Presence of FLT3 abnormalities
    • FAB M6 or M7
    • Adverse cytogenetics
    • Myelodysplastic Syndrome
    • Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:
    • Refractory to standard induction therapy (time to CR >4 weeks)
    • Recurrent (in CR ≥ 2)
    • WBC count >30,000/mcL at diagnosis
    • Age >30 at diagnosis
  • Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.
  • Chronic Myelogenous Leukemia in accelerated phase or blast crisis
  • Biphenotypic or undifferentiated leukemia
  • Burkitt's leukemia or lymphoma
  • Lymphoma:
  • Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT
  • Marginal zone or follicular lymphoma that is progressive after at least two prior therapies
  • Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT
  • Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status
  • Adequate organ function:
  • Cardiac - LVEF >45%, or shortening fraction >25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death
  • Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted;
  • Renal - serum Cr < 1.5 times the upper limit of normal for age or GFR ≥ 50 ml/min/1.73m2
  • Hepatic - total bilirubin level < 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase ≤ 5 times upper limit of normal.
  • Performance Status Karnofsky or Lansky score ≥ 70%.
  • Informed Consent must be obtained prior to initiating conditioning therapy.
  • Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.

Exclusion Criteria:

  • Availability of 10/10 or 9/10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant
  • Autologous HSCT < 6 months prior to proposed UCB transplant
  • Pregnant or breast feeding
  • Current uncontrolled infection
  • Evidence of HIV infection or positive HIV serology

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03016806


Contacts
Contact: Jane L Liesveld, MD 585-275-4099 jane_liesveld@urmc.rochester.edu
Contact: Michael W Becker, MD 585-275-4099 michael_becker@urmc.rochester.edu

Locations
United States, New York
Wilmot Cancer Institute Recruiting
Rochester, New York, United States, 14642
Contact: Jane L Liesveld, MD    585-275-4099    jane_liesveld@urmc.rochester.edu   
Contact: Michael W Becker, MD    585-275-4099    michael_becker@urmc.rochester.edu   
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Jane L Liesveld, MD Medical Director, Blood & Marrow Transplant Unit

Responsible Party: Jane Liesveld, Clinical Director, BMT Unit, University of Rochester
ClinicalTrials.gov Identifier: NCT03016806     History of Changes
Other Study ID Numbers: UBMT 15029
First Posted: January 11, 2017    Key Record Dates
Last Update Posted: February 20, 2018
Last Verified: February 2018

Additional relevant MeSH terms:
Disease
Leukemia
Multiple Myeloma
Myelodysplastic Syndromes
Preleukemia
Anemia, Aplastic
Metabolic Diseases
Immunologic Deficiency Syndromes
Hematologic Diseases
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Marrow Diseases
Precancerous Conditions
Anemia
Cyclophosphamide
Fludarabine phosphate
Melphalan
Busulfan
Fludarabine